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Studies examining the relationship between caseload and sur-
gical practice in breast cancer have generally involved a small
number of units or patients, and have been based on outdated
practice patterns. We aimed to examine the caseload volume of
screening units and individual breast cancer surgeons, and to
investigate the relationship between these volumes and practice
patterns in the contemporary setting.
The non-operative and operative history of screen-detected
breast cancers, diagnosed in women who were screened between
2000 and 2008 within the UK Breast Screening Programme, was
extracted from national databases. This information was then
correlated with unit- and individual surgeon caseload.
There were 14,008,192 screening events and 110,912 cancers
detected over the study period. No differences were seen between
practice patterns in the low- versus high-volume units. The per-
centage of surgeons seeing P30 cases of breast cancer per year
rose from 35.4% to 51.6%, whilst the number of surgeons respon-
sible for <10 cases annually decreased from 32.9% to 23.5%, over
the study period. There was a positive correlation between the
number of cancers seen by individual surgeons and the rate at
which they employed SNB (p < 0.001), and performed immediate
breast reconstruction (p < 0.001).The number of mastectomies
performed was approximately 4% lower in surgeons with high
caseload versus those with a low caseload (p = 0.035).
Whilst many surgeons are still practicing out-with ABS at
BASO guidelines, significant improvements have been made.
The important variable in terms of practice patterns is the num-
ber of cancers each individual surgeon deals with; the caseload of
individual units is less important.
doi:10.1016/j.ejcsup.2010.06.082
O-82 THE INFLUENCE OF MODE OF PRESENTATION ON THE
PATTERN OF RECURRENCE IN EARLY BREAST CANCER (EBC)
J. Mansell, C.R. Wilson, W.J. Angerson, J.C. Doughty. Western
Infirmary, Glasgow, UK
Introduction: An early peak in recurrence exists in women with
EBC. This may be explained by underlying tumour biology or a
reaction to surgery. Screen detection has been shown to have a
prognostic effect independent of disease stage suggesting a con-
nection with underlying tumour biology. We aim to determine if
the pattern of recurrence differs between modes of presentation.
Methods: Data from 3 centres in Glasgow of consecutive
women aged between 50 and 65 years with early stage breast can-
cer (EBC) diagnosed between 1995 and 2001 were examined.
Recurrence was defined as invasive disease at any site. Patients
were grouped by mode of presentation into screen detection
and symptomatic. Kaplan–Meier and time dependent Cox analy-
sis were performed.
Results: Women (1534) were included with a median follow-up
of 5.5 years. Mode of presentation was screening in 1007 (65.6%)
women. At 2.5 years cumulative recurrence was 2.5% (95% CI
1.5–3.5) in the screen detected group and 9.7% (7.2–12.2) in the
symptomatic group. At 5 years the corresponding rates were
7.8% (6.0–9.6) versus 19.1% (15.6–22.6). Time dependent multivar-
iate analysis showed that the difference in the risk of recurrence
between the modes of presentation was significantly different
within 2.5 years from diagnosis compared with later than
2.5 years (p = 0.019). The hazard ratio for recurrence within
2.5 years was 0.59 (95% CI 0.34–1.00, p = 0.05) and after 2.5 years
was 1.23 (0.84–1.80, p = 0.285).
Conclusions: These results suggest that women with screen
detected cancers have a better prognosis initially following diag-
nosis independent of disease stage but that this benefit does
not persist.
doi:10.1016/j.ejcsup.2010.06.083
O-83 DIGITAL INFRARED IMAGING FOR BREAST CANCER
DETECTION IN YOUNGER WOMEN UNDERGOING BREAST
BIOPSY
G.C. Wishart, M.S. Campisi, D. Chapman, V. Shackleton, S. Iddles,
A. Hallett, P.D. Britton. Cambridge Breast Unit, Cambridge, UK
Background: Mammography has a lower sensitivity for breast
cancer detection in younger women and those with dense
breasts. Recent improvements in digital infrared breast imaging
suggest there may be a role for this technology and we have stud-
ied its performance in 100 women prior to breast needle core
biopsy (CB) with ethical approval.
Methods: All patients were imaged using a digital infrared
breast (DIB) scan (Sentinel BreastScane) prior to breast biopsy.
Analysis of the infrared scans was performed, blinded to biopsy
results, in four different ways: Sentinel screening report, Sentinel
artificial intelligence (neural network), expert manual review and
NoTouch BreastScan a novel artificial intelligence programme.
Results: Of 106 biopsies performed in 100 women 65 were
malignant and 41 were benign. Sensitivity of Sentinel screening
(53%) and Sentinel neural network (48%) was low but analysis
with NoTouch software (70%) was much closer to expert manual
review (78%). Sensitivity (78%) and specificity (75%) using
NoTouch BreastScan were higher in women under 50 and the
combination of mammography and DIB, with NoTouch interpre-
tation, in this age group resulted in a sensitivity of 89%.
Conclusion: DIB using NoTouch BreastScan is an effective
adjunctive test for breast cancer detection in women under 70
and appears to be particularly effective in women under 50 where
maximal sensitivity (78%) and specificity (75%) were observed.
The combined sensitivity of NoTouch BreastScan and mammog-
raphy in women under 50 was encouraging at 89%, suggesting a
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potential way forward for a dual imaging approach in this youn-
ger age group.
doi:10.1016/j.ejcsup.2010.06.084
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INTERPRETATION OF FULL-FIELD DIGITAL MAMMOGRAPHY
WITH DIGITAL BREAST TOMOSYNTHESIS
Rema K. Wasan, Asif Iqbal, David R. Evans, Clare Peacock, Juliet C.
Morel, Abdel Douiri, Michael J. Michell. King’s College Hospital,
UK. King’s College London, UK
Objective: The purpose of the current study was to compare the
diagnostic accuracy of two-view full-field digital mammography
(FFDM) with co-registered two-view digital breast tomosynthesis
(DBT).
Methods: The ethics committee approved trial evaluating a
Hologic Selenia Dimensions machine recruited women recalled
after their initial breast screening using analogue film-screen
mammography, scheduled to undergo further breast assessment
following informed consent. Radiologists fulfilling the profes-
sional criteria for National Health Service Breast Screening Pro-
gramme’s radiology practice reviewed all images using the Royal
College of Radiologists Breast Group classification for mammo-
graphic features 1–5 (M1 = normal, M2 = benign, M3 = probably
benign, M4 = suspicious, M5 = malignant).
Results: The study included bilateral mammograms of 526
women (age range 47–73 years) with 119 (22.6%) histologically
proven primary breast cancers assessed by 5 readers.
Using receiver operating characteristic (ROC) test, the analysis
yielded statistically significant difference (p = 0.0001) between
FFDM and DBT. The area under the ROC curve (AUC) was
0.968 ± 0.007 for DBT compared to AUC of 0.913 ± 0.015 for FFDM,
demonstrating DBT interpretation was superior.
Conclusion: Patients recalled after routine screening mammog-
raphy will benefit from DBT as an additional technique for diag-
nostic workup.
doi:10.1016/j.ejcsup.2010.06.085
O-85 WHAT DO CLINICIANS IN THE UK DO ONCE A PATIENT
HAS RECEIVED 5 YEARS OFADJUVANT HORMONAL AROMATASE
INHIBITOR (AI) CONTAINING TREATMENT?
Claire Gaunt, Daniel Rea. CRUK Clinical Trials Unit, University of
Birmingham, Birmingham, UK
Background: NICE guidelines advocate use of AIs within licence
for all but low risk patients. Early discharge at three years is also
recommended. To gauge interest in extended adjuvant endocrine
therapy research treatment practice and follow up practice needs
to be understood.
Methods: A survey designed to capture current practice for ER
positive, post-menopausal women who have completed 5 years
of treatment with an AI was distributed to 774 oncologists and
surgeons from 285 centres across the UK. The survey also cap-
tured opinion on a proposed trial of further treatment in this
patient group.
Results: A total of 159 clinicians (65 clinical oncologists; 28
medical oncologists; 63 surgeons and 3 others) responded to the
survey, representing 102 hospitals. The most common time for
routine discharge was 5 years regardless of nodal involvement
58% vs 12% before and 23% after 5 years. Patients with more than
4 nodes positive were discharged later than 5 years by 36%
respondents. The majority of respondents discontinue AIs at 5
years for node negative but continue AI use beyond 5 years in
node positive cases.
92% of responders expressed interest in participating in a clin-
ical trial of extended endocrine therapy most frequently selecting
node positive cases as the target population.
Conclusions: There is substantial variation in follow-up practice
and treatment for ER positive, post-menopausal women following
5 years of AI containing endocrine therapy within the UK. Many
clinicians would support a clinical trial of extended hormone
therapy in node positive patients.
doi:10.1016/j.ejcsup.2010.06.086
O-86 MASTECTOMY AND RECONSTRUCTION IN STAGE IV
BREAST CANCER: A SURVEY OF UK BREAST AND PLASTIC
SURGEONS
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Harris a. aDepartment of Plastic Surgery, Royal Marsden Hospital,
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Introduction: The number of women with stage IV disease who
have primary or delayed breast reconstruction is small. The pri-
mary aim of this study was to establish current UK practice and
opinions with regards to the appropriateness of breast recon-
struction in stage IV disease.
Methods: All 485 full members of the Association of Breast Sur-
geons (ABS) and all 378 full members of the British Association of
Plastic Reconstructive and Aesthetic Surgeons (BAPRAS) were
invited by email to take part in an online survey.
Results: Of the breast surgeons, 101 responded (26.9%). Of the
plastic surgeons 59 responded (16%). 78.9% would operate on
the primary tumour, mainly for local control. Plastic surgeons
showed a propensity for immediate reconstruction compared to
their breast surgery colleagues, and 26.6% of breast surgeons
would not offer reconstruction at all. Immediate latissimus dorsi
(LD) flap and implant was the favoured method in early stage dis-
ease (100%), with delayed LD and implant the most popular
option for stage IV disease (77.0%).
In patients who have already had a mastectomy, the majority
(54.4%) would offer reconstruction if stability of disease progres-
sion has been demonstrated.
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